Company
Headquarters: Hellerup, Denmark
Employees: 639
CEO: Mr. Jan Moller Mikkelsen
$13.03 Billion
USD as of Jan. 1, 2026
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 à/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
| Last Financial Reports Date | Sept. 30, 2025 |
| Revenue TTM | $758.1 M |
| EBITDA | $-156,780,652 |
| Gross Profit TTM | $658.1 M |
| Profit Margin | -36.03% |
| Operating Margin | 5.15% |
| Quarterly Revenue Growth | 269.40% |
Ascendis Pharma A/S has the following listings and related stock indices.
Stock: NASDAQ: ASND
Stock: Bovespa: A1SN34
Stock: FSX: A71